Off-label use of baclofen: A response to Kattula
Indian Journal of Medical Ethics · 2025
DOI: 10.20529/ijme.2025.073 ↗Kurz gefasst
Kommentar in der Zeitschrift Indian Journal of Medical Ethics, 2025. Verfasst von Florian Naudet und 1 weiteren Autor:innen. Beteiligte Einrichtung: Professor of Therapeutics, Department of Psychiatry, University hospital of Rennes, Rennes, France. Hauptthemen laut MEDLINE: Baclofen, Off-Label Use, Muscle Relaxants, Central, Muscle Spasticity.
Abstract (Originalsprache)
The “discussion” on our commentary about baclofen use in India perpetuates misconceptions. We want to: a) highlight the flood of overlapping and conflicting meta-analyses that obscure rather than clarify baclofen’s effects; b) stress the importance of pivotal trials which support hypothetico-deductive reasoning and provide the basis for regulatory decisions. Such trials use only high-dose baclofen without proven benefit but serious safety concerns, including mortality. Practitioner enthusiasm, lived experience, or off-label consensus — whether in the global North or recycled in the global South — cannot replace rigorous trial evidence. We call for careful evaluation of pivotal evidence and robust research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Professor of Therapeutics, Department of Psychiatry, University hospital of Rennes, Rennes, France.
- Independent Researcher; Ex-chief, Alcohol Treatment Unit, University Hospital of Amiens, France.
Zitieren
APA
Naudet, F., & Braillon, A. (2025). Off-label use of baclofen: A response to Kattula. Indian Journal of Medical Ethics. https://doi.org/10.20529/ijme.2025.073
Vancouver
Naudet F, Braillon A. Off-label use of baclofen: A response to Kattula. Indian Journal of Medical Ethics. 2025. doi:10.20529/ijme.2025.073
BibTeX
@article{Naudet2025,
author = {Naudet, Florian and Braillon, Alain},
title = {Off-label use of baclofen: A response to Kattula},
journal = {Indian Journal of Medical Ethics},
year = {2025},
doi = {10.20529/ijme.2025.073}
}
EUVIMED